Please Wait
Applying Filters...
menu
    • menu
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    An Enquiry

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Linerixibat

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 436,364Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    After Alfasigma licensing deal, Lynavoy picks up FDA nod
    After Alfasigma licensing deal, Lynavoy picks up FDA nod

    19 Mar 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/alfasigmas-690m-gsk-buy-lynavoy-widens-pbc-space-fda-approval-rare-liver-disease

    FIERCE PHARMA
    19 Mar 2026
    Share Share
    Glaxosmithkline’s Lynavoy Receives Approval in US
    Glaxosmithkline’s Lynavoy Receives Approval in US

    17 Mar 2026

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220295

    FDA
    17 Mar 2026
    Share Share
    Alfasigma's $690M Deal For GSK Itch Drug Awaiting FDA Decision
    Alfasigma's $690M Deal For GSK Itch Drug Awaiting FDA Decision

    09 Mar 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/alfasigma-pens-690m-deal-gsk-itching-drug-awaiting-fda-approval-decision

    FIERCE BIOTECH
    09 Mar 2026
    Share Share
    FDA Accepts NDA for Linerixibat in PBC-Related Itch
    FDA Accepts NDA for Linerixibat in PBC-Related Itch

    07 Jun 2025

    // PRESS RELEASE

    https://www.gsk.com/en-gb/media/press-releases/linerixibat-new-drug-application-nda-accepted-for-review-by-the-us-fda/

    PRESS RELEASE
    07 Jun 2025
    Share Share
    GSK posts phase 3 itch data as it closes in on FDA approval
    GSK posts phase 3 itch data as it closes in on FDA approval

    09 May 2025

    // PRESS RELEASE

    https://www.gsk.com/en-gb/media/press-releases/glisten-phase-iii-trial-results-show-linerixibat-significantly-improves-cholestatic-pruritus/

    PRESS RELEASE
    09 May 2025
    Share Share
    GSK’s itch prospect hits mark in phase 3 liver disease trial
    GSK’s itch prospect hits mark in phase 3 liver disease trial

    20 Nov 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/gsk-scratches-itch-phase-3-win-hitting-goal-liver-disease-trial-open-untapped-market

    FIERCE BIOTECH
    20 Nov 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.